MOUNTAIN VIEW, Calif., Dec. 3 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. today announced that the company, will participate in a panel discussion titled "Adapting Specialty Pharma Strategy To Market Conditions" at the 2008 RBC Capital Markets Healthcare Conference on Wednesday, December 10, 2008, at 10:00 am (ET) in New York City.
A live webcast of the panel discussion will be available on the Investor Relations section of MAP Pharmaceuticals' website at http://www.mappharma.com/. A replay will also be available within 24 hours for seven days following the presentation.
About MAP Pharmaceuticals, Inc.
MAP Pharmaceuticals is dedicated to developing and commercializing new therapies for children and adults suffering from chronic conditions that are not adequately treated by currently available medicines. The company has two product candidates in Phase 3 clinical trials. Unit Dose Budesonide is being developed for the potential treatment of pediatric asthma, and MAP0004 is being developed for the potential treatment of migraine. MAP Pharmaceuticals generates new pipeline opportunities by applying its proprietary drug particle and inhalation technologies to enhance the therapeutic benefits of proven drugs, while minimizing risk, by capitalizing on their known safety, efficacy and history.
Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com/.
